Close

Merck (MRK) Announces FDA Priority Review for KEYTRUDA sBLA in Microsatellite Instability-High Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/19/2024

1. NFLX
2. TSM
3. ISRG
4. TSLA
5. SPY
6. INFY
7. SNV
8. SMCI
9. SLB
10. PPG


Go back to Merck (MRK) Announces FDA Priority Review for KEYTRUDA sBLA in Microsatellite Instability-High Cancer
Merck & Co. (NYSE: MRK) Delayed: 125.78 +0.55 (0.44%)
Previous Close $125.23    52 Week High $65.46 
Open $125.65    52 Week Low $47.97 
Day High $126.12    P/E 85.56 
Day Low $124.89    EPS $1.47 
Volume 9,403,249